HUP0300709A3 - Pharmaceutical composition comprising pemetrexed together with monothiaglycerol l-cystein or thioglycolic acid - Google Patents

Pharmaceutical composition comprising pemetrexed together with monothiaglycerol l-cystein or thioglycolic acid

Info

Publication number
HUP0300709A3
HUP0300709A3 HU0300709A HUP0300709A HUP0300709A3 HU P0300709 A3 HUP0300709 A3 HU P0300709A3 HU 0300709 A HU0300709 A HU 0300709A HU P0300709 A HUP0300709 A HU P0300709A HU P0300709 A3 HUP0300709 A3 HU P0300709A3
Authority
HU
Hungary
Prior art keywords
monothiaglycerol
cystein
pharmaceutical composition
thioglycolic acid
pemetrexed
Prior art date
Application number
HU0300709A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0002691A external-priority patent/GB2358799A/en
Priority claimed from GB0019599A external-priority patent/GB2365768A/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HUP0300709A2 publication Critical patent/HUP0300709A2/hu
Publication of HUP0300709A3 publication Critical patent/HUP0300709A3/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HU0300709A 2000-02-04 2001-01-23 Pharmaceutical composition comprising pemetrexed together with monothiaglycerol l-cystein or thioglycolic acid HUP0300709A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0002691A GB2358799A (en) 2000-02-04 2000-02-04 A pharmaceutical composition comprising pemetrexed and an antioxidant
GB0019599A GB2365768A (en) 2000-08-09 2000-08-09 Stable liquid composition containing pemetrexed
PCT/US2001/000648 WO2001056575A1 (en) 2000-02-04 2001-01-23 Pharmaceutical composition comprising pemetrexed together with monothioglycerol l-cystein or thioglycolic acid

Publications (2)

Publication Number Publication Date
HUP0300709A2 HUP0300709A2 (hu) 2003-07-28
HUP0300709A3 true HUP0300709A3 (en) 2005-04-28

Family

ID=26243579

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300709A HUP0300709A3 (en) 2000-02-04 2001-01-23 Pharmaceutical composition comprising pemetrexed together with monothiaglycerol l-cystein or thioglycolic acid

Country Status (31)

Country Link
EP (1) EP1265612B1 (hu)
JP (1) JP2003521518A (hu)
KR (1) KR20020081293A (hu)
CN (1) CN1396828A (hu)
AR (1) AR027360A1 (hu)
AT (1) ATE267601T1 (hu)
AU (1) AU3442201A (hu)
BR (1) BR0107958A (hu)
CA (1) CA2399124A1 (hu)
CO (1) CO5280222A1 (hu)
CZ (1) CZ20022654A3 (hu)
DE (1) DE60103512T2 (hu)
DK (1) DK1265612T3 (hu)
DZ (1) DZ3269A1 (hu)
EA (1) EA004708B1 (hu)
ES (1) ES2220716T3 (hu)
HK (1) HK1052461A1 (hu)
HR (1) HRP20020636A2 (hu)
HU (1) HUP0300709A3 (hu)
IL (1) IL150475A0 (hu)
MX (1) MXPA02007191A (hu)
MY (1) MY129450A (hu)
NO (1) NO20023379L (hu)
NZ (1) NZ519727A (hu)
PE (1) PE20011223A1 (hu)
PL (1) PL356705A1 (hu)
PT (1) PT1265612E (hu)
SK (1) SK10982002A3 (hu)
SV (1) SV2002000301A (hu)
TR (1) TR200401436T4 (hu)
WO (1) WO2001056575A1 (hu)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050042280A1 (en) * 2001-12-28 2005-02-24 Rogers Tracey L. Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol
KR101069128B1 (ko) * 2011-03-10 2011-09-30 건일제약 주식회사 페메트렉시드 또는 그의 염을 포함하는 항산화제-비함유 주사용 용액 형태의 약학적 제제의 제조방법
KR20130122065A (ko) * 2012-04-30 2013-11-07 씨제이제일제당 (주) 페메트렉시드를 함유하는 안정화된 주사용 액상 제제
EP2666463A1 (en) 2012-05-21 2013-11-27 Synthon BV Stabilized liquid composition comprising pemetrexed
DE102012010774A1 (de) 2012-05-31 2013-12-05 Stada Arzneimittel Ag Pharmazeutische Pemetrexed-Lösung
KR101260636B1 (ko) * 2012-11-29 2013-05-13 씨제이제일제당 (주) 안정화된 페메트렉시드 제제
KR101485243B1 (ko) * 2013-05-08 2015-01-21 씨제이헬스케어 주식회사 안정화된 페메트렉시드 제제
JP6094388B2 (ja) * 2013-06-07 2017-03-15 ニプロ株式会社 ペメトレキセドを含む注射用組成物
CN103340826B (zh) * 2013-07-05 2015-09-09 浙江震元制药有限公司 美他多辛注射用组合物及其制备方法
JP6313317B2 (ja) 2013-10-03 2018-04-18 富士フイルム株式会社 注射液製剤及びその製造方法
KR101703980B1 (ko) 2013-12-30 2017-02-08 주식회사 삼양바이오팜 항산화제를 함유하지 않는 약학 조성물 및 그의 제조방법
EP3124026B1 (en) * 2014-03-28 2018-07-25 Fujifilm Corporation Injection preparation and method for producing same
WO2016024369A1 (ja) * 2014-08-13 2016-02-18 テバ製薬株式会社 がん治療用医薬組成物
ES2775582T3 (es) 2014-10-16 2020-07-27 Synthon Bv Composición farmacéutica líquida que comprende pemetrexed
KR101770605B1 (ko) * 2014-11-17 2017-08-23 동아에스티 주식회사 페메트렉시드 또는 그것의 약제학적으로 허용가능 한 염을 함유하는 안정한 약제학적 조성물
KR101919436B1 (ko) 2015-05-28 2018-11-16 주식회사 삼양바이오팜 안정화된 약학 조성물 및 그의 제조방법
KR101693675B1 (ko) * 2015-12-14 2017-01-06 주식회사 종근당 페메트렉시드 또는 그의 약제학적으로 허용가능한 염을 함유하는 안정화된 약학조성물
US20170239250A1 (en) 2016-02-19 2017-08-24 Eagle Pharmaceuticals, Inc. Pemetrexed formulations
JP2019094284A (ja) * 2017-11-21 2019-06-20 日本化薬株式会社 ペメトレキセドを含有する注射用溶液製剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0162654B1 (ko) * 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체

Also Published As

Publication number Publication date
DE60103512T2 (de) 2005-06-02
MY129450A (en) 2007-04-30
MXPA02007191A (es) 2002-12-09
DZ3269A1 (fr) 2001-08-09
EP1265612B1 (en) 2004-05-26
IL150475A0 (en) 2002-12-01
EP1265612A1 (en) 2002-12-18
CN1396828A (zh) 2003-02-12
EA200200831A1 (ru) 2003-02-27
HK1052461A1 (en) 2003-09-19
PL356705A1 (en) 2004-06-28
BR0107958A (pt) 2002-10-29
NZ519727A (en) 2004-04-30
WO2001056575A1 (en) 2001-08-09
ES2220716T3 (es) 2004-12-16
KR20020081293A (ko) 2002-10-26
HRP20020636A2 (en) 2003-10-31
DE60103512D1 (de) 2004-07-01
HUP0300709A2 (hu) 2003-07-28
CA2399124A1 (en) 2001-08-09
DK1265612T3 (da) 2004-08-09
SV2002000301A (es) 2002-06-07
PT1265612E (pt) 2004-08-31
JP2003521518A (ja) 2003-07-15
NO20023379D0 (no) 2002-07-12
CO5280222A1 (es) 2003-05-30
CZ20022654A3 (cs) 2003-01-15
EA004708B1 (ru) 2004-06-24
NO20023379L (no) 2002-09-30
SK10982002A3 (sk) 2003-03-04
AR027360A1 (es) 2003-03-26
ATE267601T1 (de) 2004-06-15
AU3442201A (en) 2001-08-14
TR200401436T4 (tr) 2004-07-21
PE20011223A1 (es) 2001-12-20

Similar Documents

Publication Publication Date Title
HUP0204137A3 (en) Pharmaceutical composition comprising fulvestrant
IL152659A0 (en) Pharmaceutical composition
HUP0300709A3 (en) Pharmaceutical composition comprising pemetrexed together with monothiaglycerol l-cystein or thioglycolic acid
IL154008A0 (en) New pharmaceutical composition
IL178128A0 (en) Salts of 3-0-(3',3'-dimethyl-succinyl) betulinic acid and pharmaceutical compositions containing the same
EP1450824A4 (en) PHARMACEUTICAL COMPOSITION
EG24078A (en) Liquid pharmaceutical composition
HUP0401638A3 (en) Thiopene-amides, thiazolesulfonamides as antineoplastic agents, and pharmaceutical composition containing the same
HUP0303163A3 (en) Tramadol-based pharmaceutical composition
GB0117057D0 (en) Pharmaceutical composition
HK1065257A1 (en) Medicinal composition
EP1408896A4 (en) PHARMACEUTICAL COMPOSITION
HK1057474A1 (en) Medicinal composition
GB0129117D0 (en) Pharmaceutical composition
IL154238A0 (en) Pharmaceutical composition
GB0116107D0 (en) Pharmaceutical composition
GB0127805D0 (en) Pharmaceutical composition
PL370037A1 (en) Pharmaceutical composition
IL158172A0 (en) Pharmaceutical compositions containing (-)-hydroxycitric acid
ZA200205112B (en) Pharmaceutical composition comprising pemetrexed together with monothioglycerol L-cystein or thioglycolic acid.
GB0114746D0 (en) Medicinal composition
SI1265612T1 (en) Pharmaceutical composition comprising pemetrexed together with monothioglycerol, l-cystein or thioglycolic acid
IL157411A0 (en) Pharmaceutical composition
GB0101094D0 (en) Pharmaceutical composition
HU0103049D0 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees